A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa

Trial Profile

A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 1 Nov 2019 to 8 May 2019.
    • 12 Sep 2017 Planned primary completion date changed from 1 Sep 2019 to 8 May 2019.
    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top